TrumpRx.gov Launched; Pharma Stocks Drop as U.S. Imposes Fourfold Pricing Rules

The U.S. Department of Health and Human Services launched TrumpRx.gov on February 5, 2026, enabling users to purchase prescription drugs directly at prices as low as 10% of list. The move follows a fourfold regulatory package aimed at curbing pricing distortions in the global pharmaceutical sector. Key provisions require manufacturers to offer the same lowest prices to Medicare and commercial insurers as to domestic purchasers, and to ensure new drugs are not priced higher abroad than in the U.S. The initiative has drawn support from AstraZeneca, Eli Lilly, Novartis, NovoNordisk, and GlaxoSmithKline, covering 40 high-cost medications. CMS Administrator Dr. Mehmet Oz said the free, price-comparison tool is expected to save about £100 million in GLP-1 drugs this year, with weight-loss medications among the steepest declines. The policy has sent制药 shares in Japan lower, including Takeda and Sony Biosciences, as reaction spreads globally. The administration argues the rules will preserve U.S. leadership in biopharma and shield consumers from escalating healthcare costs, while offering manufacturers tariff exemptions in exchange. Implementation faces uncertainty, with manufacturers warning of reduced R&D incentives and consumers likely to favor insurance-covered options.